Last reviewed · How we verify

Sutent — Competitive Intelligence Brief

Sutent (sunitinib) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Moderate Risk QT Prolonging Agents. Area: Oncology.

marketed Moderate Risk QT Prolonging Agents 3-phosphoinositide-dependent protein kinase 1 Oncology Live · refreshed every 30 min

Target snapshot

Sutent (sunitinib) — Pfizer. Sunitinib is a small-molecule, multi-targeted receptor tyrosine kinase inhibitor that inhibits PDGFRα, PDGFRβ, VEGFR1, VEGFR2, and KIT.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Sutent TARGET sunitinib Pfizer marketed Moderate Risk QT Prolonging Agents 3-phosphoinositide-dependent protein kinase 1 2006-01-01
Sunitinib Malate sunitinib-malate Pfizer marketed Moderate Risk QT Prolonging Agents 3-phosphoinositide-dependent protein kinase 1 2006-01-01
celebrex celebrex POZEN marketed 3-phosphoinositide-dependent protein kinase 1, Adenosine receptor A3, Cytochrome c oxidase subunit 2
Simdax LEVOSIMENDAN phase 3 Moderate Risk QT Prolonging Agents Troponin C, slow skeletal and cardiac muscles

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Moderate Risk QT Prolonging Agents class)

  1. Pfizer · 2 drugs in this class
  2. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sutent — Competitive Intelligence Brief. https://druglandscape.com/ci/sunitinib. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: